Technology Papers

Efficient capture of circulating tumor cells with a novel immunocytochemical microfluidic device 

 Conclusion:
 1.   Overall, data concluded that the CEE system conforms to simple physical principles
and that it robustly and efficiently captures tumor cells under a variety of operating conditions.
2.  There is a clear two step recommendation. First, clinicians should employ antibody cocktails with a common capture principle, here biotin, in order to maximize relevant cell capture.  Second, while the data presented here show that in most cases with sufficient surface antibody density, greater than 70% capture was achieved, a channel design which forces variations in flow velocities along the channel length may overcome potential inefficiencies in capture seen at low antigen densities. 

There is a clear two step recommendation. First, clinicians should employ antibody cocktails

Mary Nora Dickson,1,2,a) Pavel Tsinberg,1 Zhongliang Tang,1, Farideh Z. Bischoff,1 Timothy Wilson,1 and Edward F. Leonard2
1Biocept, Inc., 5810 Nancy Ridge Drive Suite 150, San Diego, California 92121, USA
2Columbia University School of Engineering and Applied Science, Department of Chemical
Engineering, 

BIO Microfluidics_Biocept Paper.pdf 

with a common capture principle, here biotin, in order to maximize relevant cell capture.18

Detection of EpCAM-negative and cytokeratin-negative circulating tumor cells in peripheral blood 

Conclusions:
1.  Study demonstrates that the peripheral blood of cancer patients contain circulating tumor cells other than those normally detected with antibodies to EpCAM and cytokeratin.
2.  The use of CEE-Enhanced and antibody mixtures along with the traditional anti-EpCAM and anti-CK approach may lead to new insight into the diagnostic applications of CTCs.

Stephen D.Mikolajczyk,1 Lisa S.Millar,1 Pavel Tsinberg,1 StephenM. Coutts,1
MaryamZomorrodi,1 TamPham,2 Farideh Z. Bischoff,2 and Tony J. Pircher1
1Research and Development, Biocept Inc., 5810 Nancy Ridge Drive, Suite 150, San Diego, CA 92121, USA
2Translational and Clinical Development, Biocept Inc., 5810 Nancy Ridge Drive, Suite 150, San Diego, CA 92121, USA

http

http://www.hindawi.com/journals/jo/2011/252361/

http://www.hindawi.com/journals/jo/2011/252361  

Second, while the data presented here show that in most cases with sufficient surface antibody

density, greater than 70% capture was achieved, a channel design which forces variations in

flow velocities along the channel length may overcome potential inefficiencies in capture seen

at low antigen densities. 

There is a clear two step recommendation. First, clinicians should employ antibody cocktails

with a common capture principle, here biotin, in order to maximize relevant cell capture.18

Second, while the data presented here show that in most cases with sufficient surface antibody

density, greater than 70% capture was achieved, a channel design which forces variations in

flow velocities along the channel length may overcome potential inefficiencies in capture seen

at low antigen densities.